Bill

HR 2202

End Taxpayer Funding of Gender Experimentation Act of 2025

119th Congress Introduced by Robert Aderholt and 19 co-sponsors

HR 2202 prohibits federal funding for gender transition procedures, impacting healthcare providers and patients seeking these services, limiting options and funding availability.

Introduced in House

WeVote Research Nonpartisan

Bill Summary · HR 2202

Summary of HR 2202 - End Taxpayer Funding of Gender Experimentation Act of 2025

Bill Information:
- Bill Number: HR 2202
- Title: End Taxpayer Funding of Gender Experimentation Act of 2025
- Status: Introduced in House
- Introduced Date: March 18, 2025
- Classification: Bill

Purpose and Intent

The End Taxpayer Funding of Gender Experimentation Act of 2025 aims to prohibit the use of federal funds for gender transition procedures. The bill seeks to address concerns regarding taxpayer money being allocated to what the sponsors describe as "gender experimentation." The legislation is part of a broader discussion on healthcare funding and gender identity issues in the United States.

Key Provisions

The bill is structured into two main titles:

TITLE I—Prohibiting Federally Funded Gender Transition Procedures

Sec. 101: This section explicitly prohibits taxpayer-funded gender transition procedures. This includes any medical or surgical interventions related to gender transition that are funded by federal resources.

TITLE II—Application under the Affordable Care Act

Sec. 201: This section clarifies how the prohibition applies to premium credits and cost-sharing reductions under the Affordable Care Act (ACA). It ensures that federal funding cannot be used for gender transition procedures in the context of ACA benefits.

Affected Parties

The bill would primarily impact:
- Healthcare Providers: Those who offer gender transition services may face restrictions on federal funding.
- Patients Seeking Transition Services: Individuals seeking gender transition procedures may find fewer options available if federal funding is prohibited.
- Insurance Companies: Insurers may need to adjust their coverage policies in response to the changes mandated by this legislation.

Legislative Actions

On March 18, 2025, the bill was referred to the Committee on Energy and Commerce, as well as the Committees on the Judiciary and Ways and Means. The Speaker will determine the period for consideration by these committees.

Related Bills

S 977: This bill serves as a companion to HR 2202, indicating that similar legislation is being considered in the Senate.

Conclusion

The End Taxpayer Funding of Gender Experimentation Act of 2025 represents a significant legislative effort to restrict federal funding for gender transition procedures. As the bill progresses through the legislative process, it will likely generate considerable debate regarding healthcare funding, individual rights, and the role of government in personal medical decisions.

Compiled from official sources — confirm details with the bill’s official record.